{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:15:11Z","timestamp":1784128511521,"version":"3.55.0"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,6,14]],"date-time":"2013-06-14T00:00:00Z","timestamp":1371168000000},"content-version":"vor","delay-in-days":164,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>This study determined the pharmacokinetics (PK) of figitumumab and its effects on insulin\u2010like growth factor (IGF) axis\u2010related biomarkers, following a single intravenous dose (10 [n = 16] and 20 [n = 12] mg\/kg) in healthy adults. Serial blood sampling for PK and biomarkers was conducted up to 84 days postdose. A dose increase from 10 to 20 mg\/kg led to 1.9\u2010 and 2.4\u2010fold increases in mean C<jats:sub>max<\/jats:sub> and AUC\u221e, respectively. Median disposition half\u2010life was 21.1 and 27.8 days at 10 and 20 mg\/kg, respectively. At 10 and 20 mg\/kg, figitumumab increased total IGF\u20101, free IGF\u20101, IGF binding protein (IGFBP)\u20133, and insulin by 4.1\u2010 and 4.8\u2010, 8.3\u2010 and 12.1\u2010, 2.4\u2010 and 2.9\u2010, and 7.3\u2010 and 9.8\u2010fold, respectively; increases were sustained throughout the 84\u2010day period. There was a slight and transient elevation in IGF\u20102. Mean plasma glucose increased by 18% and 16% at 10 and 20 mg\/kg, respectively. Most treatment\u2010related adverse events were mild in severity; the most common included dry eye (n = 9) and ocular hyperemia (n = 9) in the 20\u2010mg\/kg group. No antidrug antibodies were detected. Overall, figitumumab (10 or 20 mg\/kg) demonstrated PK properties typical of IgG2 antibodies and produced substantial and sustained increases in IGF\u20101 (total and free), IGFBP\u20103, and insulin.<\/jats:p><\/jats:sec>","DOI":"10.1177\/0091270011432934","type":"journal-article","created":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T02:06:43Z","timestamp":1327025203000},"page":"21-28","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics and Pharmacodynamics of Figitumumab, a Monoclonal Antibody Targeting the Insulin\u2010Like Growth Factor 1 Receptor, in Healthy Participants"],"prefix":"10.1002","volume":"53","author":[{"given":"Donghua","family":"Yin","sequence":"first","affiliation":[{"name":"Oncology Business Unit, Pfizer, Inc  Groton, CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sleight","sequence":"additional","affiliation":[{"name":"Oncology Business Unit, Pfizer, Inc  Groton, CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Alvey","sequence":"additional","affiliation":[{"name":"Primary Care Business Unit, Pfizer, Inc  Groton, CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne G.","family":"Hansson","sequence":"additional","affiliation":[{"name":"New Haven Clinical Research Unit, Pfizer, Inc  New Haven, CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akintunde","family":"Bello","sequence":"additional","affiliation":[{"name":"Oncology Business Unit, Pfizer, Inc  New York, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrc.10022"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1096-6374(03)00038-8"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000090640"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4879"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2536"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1358\/dnp.2003.16.8.829351"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.03.001"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00024677-200201060-00005"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.6.8.1135"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1070"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9319"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1118"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605767"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70354-7"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ba2f1d"},{"key":"e_1_2_8_17_1","article-title":"phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non\u2010small cell lung cancer (NSCLC)","author":"Jassem J","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0089"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605972"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1083-9"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010991313633"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2008-0028"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2003.00827.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270011432934","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270011432934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T08:22:58Z","timestamp":1698654178000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270011432934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1177\/0091270011432934"],"URL":"https:\/\/doi.org\/10.1177\/0091270011432934","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}